Rifapentine
Sold as Priftin, Fripnit, Inecabitin, Soloprif, Rifeods, Fripnit odt, Rifapentine adco
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 5
- Registrations
- 9
- Schedule source
- SAHPRA documentation
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Sanofi-aventis South Africa (Pty) LtdCertificate held by Sanofi-aventis South Africa (Pty) Ltd. | Priftin | 150 mg | 511081 | S4 | PIPIL |
| Pharma Dynamics (Pty) Ltd | Fripnit, Fripnit odt | 150 mg, 300 mg | 570176, 590350 | S4 | PIPIL |
| Austell Pharmaceuticals (Pty) Ltd | Inecabitin | Not stated | 570499 | S4 | None |
| Macleods Pharmaceuticals SA (Pty) Ltd | Soloprif, Rifeods | 150 mg, 300 mg | 570590, 570591.590, 580101, 580102.101 | S4 | None |
| Adcock ingram limited | Rifapentine adco | 300 mg | 590600 | S4 | PIPIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Priftin EACH TABLET CONTAINS :RIFAPENTINE 150,0 mg | 150 mgFilm-coated tablets. | 51108151/20.2.3/1081Approved 21 June 2022 | Registered | S4 | PIPIL |
| Fripnit EACH TABLET CONTAINS RIFAPENTINE 300,0 mg | 300 mgTablet | 57017657/20.2.3/0176Approved 24 March 2023 | Registered | S4 | PIPIL |
| Inecabitin EACH TABLET CONTAINS RIFAPENTINE 300,0 mg | Not listed | 57049957/20.2.3/0499 | Registered | S4 | None |
| Soloprif 300 MG EACH TABLET CONTAINS RIFAPENTINE 300,0 mg | 300 mg | 57059057/20.2.3/0590 | Registered | S4 | None |
| Rifeods 300 MG EACH TABLET CONTAINS RIFAPENTINE 300,0 mg | 300 mg | 570591.59057/20.2.3/0591.590 | Registered | S4 | None |
| Soloprif 150 MG EACH TABLET CONTAINS RIFAPENTINE 150,0 mg | 150 mg | 58010158/20.2.3/0101 | Registered | S4 | None |
| Rifeods 150 MG EACH TABLET CONTAINS RIFAPENTINE 150,0 mg | 150 mg | 580102.10158/20.2.3/0102.101 | Registered | S4 | None |
| Fripnit 150 MG odt EACH TABLET CONTAINS: RIFAPENTINE 150,0 mg | 150 mg | 59035059/20.2.3/0350 | Registered | S4 | None |
| Rifapentine 300 adco EACH TABLET CONTAINS:RIFAPENTINE 300,0 mg | 300 mgFilm coated tablets | 59060059/20.2.3/0600Approved 27 January 2026 | Registered | S4 | PIPIL |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Rifapentine
S4: Rifapentine
Consolidated Schedules 06 July 2026, line 7804
Pharmacological class: Tuberculostatics. (class 20.2.3)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Priftin, Sanofi-aventis South Africa (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.